Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

Bibliography

• Marty M, Cognetti F, Maraninchi D, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23(19):4265-74
   PubMed Web of Science ®Google Scholar
• . Madarnas Y, Trudeau M, Franek JA, Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 2008;34(6):539-57
   PubMed Web of Science ®Google Scholar
• Metro G, Mottolese M, Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother 2008;9(15):2583-601
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43
   PubMed Web of Science ®Google Scholar
• Gomez HL, Doval DC, Chavez MA, Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26(18):2999-3005
   PubMed Web of Science ®Google Scholar
• Liu L, Greger J, Shi H, Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009;69(17):6871-8
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Press M, A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112(3):533-43
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Moroni M, Veronese S, Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007;25(22):3238-45
   PubMed Web of Science ®Google Scholar
• Moroni M, Veronese S, Benvenuti S, Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6(5):279-86
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97(9):643-55
   PubMed Web of Science ®Google Scholar
• Szabo B, Nelhubel GA, Karpati A, Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol 2011;47(6):487-96
   PubMed Web of Science ®Google Scholar
• Gilbert JA, Goetz MP, Reynolds CA, Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther 2008;7(4):944-51
   PubMed Web of Science ®Google Scholar
• Gumuskaya B, Alper M, Hucumenoglu S, EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genet Cytogenet 2010;203(2):222-9
   PubMedGoogle Scholar
• Nakajima H, Ishikawa Y, Furuya M, Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast Cancer 2012; DOI: 10.1007/s12282-012-0354-1
   Web of Science ®Google Scholar
• Souka E, Alexiadis E, Theohari I, Exon 8 amplification of epidermal growth factor receptor (EGFR) in invasive breast carcinomas. Histopathology 2012;61:644-51
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 2010;7(2):98-107
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-16
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131(1):18-43
   PubMed Web of Science ®Google Scholar
• Han SW, Cha Y, Paquet A, Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. PLoS One 2012;7(7):e39943
   PubMed Web of Science ®Google Scholar
• Spector NL, Xia W, Burris H, Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23(11):2502-12
   PubMed Web of Science ®Google Scholar
• Press MF, Finn RS, Cameron D, HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 2008;14(23):7861-70
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Varella-Garcia M, Finocchiaro G, Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008;99(1):83-9
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA, Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21(20):3798-807
   PubMed Web of Science ®Google Scholar
• Frattini M, Saletti P, Romagnani E, PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007;97(8):1139-45
   PubMed Web of Science ®Google Scholar
• Algars A, Lintunen M, Carpen O, EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. Br J Cancer 2011;105(2):255-62
   PubMed Web of Science ®Google Scholar
• Toyama T, Yamashita H, Kondo N, Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer 2008;8:309
   PubMed Web of Science ®Google Scholar
• Lv N, Xie X, Ge Q, Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations. Diagn Pathol 2011;6:118
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortes J, Kim SB, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med 2012;367:1783-91
   PubMed Web of Science ®Google Scholar